|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,940.00 GBX | -3.34% |
|
+1.81% | +6.33% |
| 07-30 | Drugmakers, retailers must face 'maximum strength' claim in decongestant false ad litigation in US | RE |
| 07-30 | GSK global supply chain director sells 38,000 shares | AN |
| Market Cap | 77.26B 104B 90.21B 83.78B 146B 9,916B 148B 992B 388B 4,925B 390B 381B 16,561B | P/E 2026 * |
12.8x | P/E 2027 * | 11.3x |
|---|---|---|---|---|---|
| Enterprise Value | 94.2B 127B 110B 102B 177B 12,089B 181B 1,209B 473B 6,004B 476B 465B 20,192B | EV / Sales 2026 * |
2.77x | EV / Sales 2027 * | 2.54x |
| Free-Float |
99.07% | Yield 2026 * |
3.59% | Yield 2027 * | 3.77% |
Last Transcript: GSK plc
| 1 day | -3.34% | ||
| 1 week | +1.81% | ||
| Current month | -2.07% | ||
| 1 month | -2.07% | ||
| 3 months | +0.60% | ||
| 6 months | +3.38% | ||
| Current year | +6.33% |
| 1 week | 1,926 |  | 2,096 |
| 1 month | 1,850.5 | | 2,096 |
| Current year | 1,690 | | 2,282 |
| 1 year | 1,288.6 | | 2,282 |
| 3 years | 1,242.5 | | 2,282 |
| 5 years | 1,242.5 | | 3,408.16 |
| 10 years | 1,242.5 | | 3,408.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | - | 31/12/2025 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 30/04/2023 |
| Chief Tech/Sci/R&D Officer | - | 30/11/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | - | 05/05/2026 |
Hal Barron
BRD | Director/Board Member | 64 | 31/12/2017 |
Jonathan Symonds
CHM | Chairman | 68 | 31/08/2019 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 12/05/26 | Free | Executive/Senior Manager | 6 | 0.0000% | ||
| 20/04/26 | Buy | Head of Human Resources | 65 | 0.0000% | ||
| 16/04/26 | Buy | Executive/Senior Manager | 154 | 0.0000% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.34% | +1.81% | +32.65% | +40.27% | 106B | |
| -4.55% | -2.61% | +51.95% | +151.91% | 1,079B | |
| -3.66% | -1.33% | +52.95% | +46.62% | 640B | |
| -2.24% | +0.19% | +35.97% | +70.64% | 465B | |
| -2.29% | +1.12% | +36.13% | +31.18% | 353B | |
| -2.28% | -0.69% | +33.42% | +40.48% | 301B | |
| -3.15% | +0.25% | +10.63% | +15.03% | 271B | |
| -2.12% | +3.31% | +1.82% | -37.38% | 228B | |
| 0.00% | +4.34% | +28.63% | +64.00% | 209B | |
| -1.09% | +0.32% | +14.40% | +70.80% | 165B | |
| Average | -1.98% | +4.85% | +29.85% | +49.36% | 381.59B | |
| Weighted average by Cap. | -1.67% | +4.87% | +37.89% | +71.98% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.99B 45.69B 39.69B 36.86B 64.03B 4,362B 65.19B 436B 171B 2,167B 172B 168B 7,286B | 35.62B 47.89B 41.6B 38.63B 67.1B 4,572B 68.32B 457B 179B 2,271B 180B 176B 7,636B |
| Net income | 6.14B 8.25B 7.17B 6.66B 11.56B 788B 11.77B 78.8B 30.85B 391B 30.99B 30.31B 1,316B | 6.96B 9.35B 8.12B 7.54B 13.11B 893B 13.34B 89.32B 34.97B 444B 35.13B 34.36B 1,491B |
| Net Debt | 16.94B 22.77B 19.78B 18.37B 31.91B 2,174B 32.48B 217B 85.14B 1,080B 85.51B 83.64B 3,631B | 13.16B 17.69B 15.37B 14.27B 24.79B 1,689B 25.24B 169B 66.15B 839B 66.44B 64.99B 2,821B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/07/26 | GBX 1,940.00 | -3.34% | 7,053,270 |
| 29/07/26 | GBX 2,007.00 | -1.08% | 8,561,515 |
| 28/07/26 | GBX 2,029.00 | +3.47% | 18,384,146 |
| 27/07/26 | GBX 1,961.00 | +2.16% | 13,332,270 |
| 24/07/26 | GBX 1,919.50 | +0.73% | 5,843,512 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GSK Stock
Select your edition
All financial news and data tailored to specific country editions
